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Abstract
In silico discovery of interactions between drug compounds and target proteins is of core importance for improving the
efficiency of the laborious and costly experimental determination of drug-target interaction. Drug-target interaction data
are available for many classes of pharmaceutically useful target proteins including enzymes, ion channels, GPCRs and
nuclear receptors. However, current drug-target interaction databases contain a small number of drug-target pairs which
are experimentally validated interactions. In particular, for some drug compounds (or targets) there is no available
interaction. This motivates the need for developing methods that predict interacting pairs with high accuracy also for these
’new’ drug compounds (or targets). We show that a simple weighted nearest neighbor procedure is highly effective for this
task. We integrate this procedure into a recent machine learning method for drug-target interaction we developed in
previous work. Results of experiments indicate that the resulting method predicts true interactions with high accuracy also
for new drug compounds and achieves results comparable or better than those of recent state-of-the-art algorithms.
Software is publicly available at http://cs.ru.nl/˜tvanlaarhoven/drugtarget2013/.
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Introduction
A core problem in pharmacology is the determination of
interactions between drug compounds and target proteins in order
to understand and study their effects. The in silico prediction of
such interactions is of crucial importance for improving the
efficiency of the laborious and costly experimental determination
of drug-target interaction (see e.g. [1–4]).
Drug-target interaction data are available for various classes of
pharmaceutically useful target proteins including enzymes, ion
channels, GPCRs and nuclear receptors [5]. Publicly available
databases have been built and maintained, such as KEGG BRITE
[6], DrugBank [7], GLIDA [8], SuperTarget and Matador [9],
BRENDA [10], and ChEMBL [11], containing drug-target
interaction and other related sources of information, like chemical
and genomic data.
The availability of these data has boosted the development of
machine learning methods for the in silico prediction of drug-
target interactions, including the seminal paper by Yamanishi
et al. [12]. In that paper the authors distinguish between
prediction for ’known’ drug compounds or targets, for which at
least one interaction is present in the training set; and prediction
for ’new’ drug compounds or targets, for which no interaction in
the training set is available. This results in four possible settings for
predicting drug-target interaction, depending on whether the drug
compounds and/or targets are known or new.
The current state-of-the-art for the in silico prediction of drug-
target interaction involves methods that employ similarity
measures for drug compounds and for targets in the form of
kernel functions, e.g., [12–19].
In this paper we generalize the applicability of the method
introduced in [16] to so-called new drug compounds, that is, drug
compounds for which no interactions are known. The method,
hereafter called GIP, uses known interactions of a drug for
predicting novel ones by means of a regularized least square
algorithm incorporating a product of kernels constructed from
drug compound and target interaction profiles. We propose a
simple weighted nearest neighbor algorithm, called WNN, for
constructing an interaction score profile for a new drug compound
using chemical and interaction information about known com-
pounds in the dataset. The WNN method can be used as a stand-
alone algorithm for predicting interactions for new drug
compounds. It can also be directly incorporated into the GIP
method for handling new drug compounds. We call the resulting
combination WNN-GIP. The methods can be directly adapted to
handle also unknown targets or both unknown drug compounds
and targets.
We test the predictive performance of WNN and WNN-GIP on
four drug-target interaction networks in humans involving
enzymes, ion channels, GPCRs and nuclear receptors. Results as
measured by the area under the curve (AUC) and area under the
precision-recall curve (AUPR) [20] show that the weighted nearest
neighbor profile algorithm and its incorporation into the GIP
method are capable to predict true interactions for new drug
compounds with satisfactory accuracy. The algorithms achieve
competitive or better results than the recent state-of-the-art
algorithms KBMF2K [15] and BLM-NII [17]. KBMF2K is based
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on a fully probabilistic approach to model drug-target interaction,
which can be applied to discover target (respectively drug
compound) interactions for new drug compounds (respectively
target proteins). Results in [15] indicate improved accuracy over
the method introduced in [19]. BLM-NII is an extension of the
BLM method [13] to deal with new drug compounds (or targets).
In BLM-NII a drug-target interaction for a new drug compound is
inferred by constructing an estimated interaction profile from the
drug compounds in the training data. The resulting profile is then
used as label information to learn an interaction model for that
drug compound with the BLM method.
Methods
The Problem
We consider the problem of predicting interactions using a
drug-target interaction network, chemical similarity between drug
compounds and genomic similarity between targets proteins.
Formally we are given a set Xd~fd1,d2, . . . ,dndg of drug
compounds and a set Xt~ft1,t2, . . . ,tntg of target proteins. A
set of interactions between drug compounds and targets is known.
A bipartite network (between drug compounds and targets) can be
constructed whose edges are such known interactions. Its
corresponding adjacency matrix is a nd|nt matrix Y such that
yij~1 if drug compound di interacts with target tj , and yij~0
otherwise. Furthermore, information about the the chemical
similarity between drug compounds and genomic similarity
between targets is given in the form of the similarity matrices Sd
and Sg, respectively.
The goal is to assign scores to drug-target pairs (di,tj ) such that
pairs with higher scores are more likely to interact.
The GIP Method
Machine learning methods for tackling this problem are mainly
based on the assumption that drug compounds exhibiting a similar
pattern of interaction and non-interaction with the targets in a
drug-target interaction network are likely to show similar
interaction behavior with respect to new targets. A similar
assumption on targets is considered. Here use the method
introduced in [16]. It is based on the so-called (target) interaction
profile ydi of a drug compound di, defined to be row i of the
adjacency matrix Y , and the (drug compound) interaction profile
yTtj of a target protein tj , defined to be column j of Y . The
interaction profiles generated from a drug-target interaction
network are used as feature vectors for a classifier. A kernel from
the interaction profiles is constructed using topology of the drug-
target network, defined for drug compounds di and dj as follows:
KGIP,d(di,dj)~ exp ({cdEydi{ydjE
2):
where
cd~~cd=(
1
nd
Xnd
i~1
Dydi D2):
A kernel KGIP,t for the similarities between target proteins is
defined analogously. Moreover, the kernels Kchemical,d and
Kgenomic,t are considered, containing information about the
chemical and genomic space. They are constructed from the
chemical and genomic similarity matrices Sd and Sg between drug
compounds and between targets, by applying a simple transfor-
mation to make them symmetric and positive definite. The
interaction profile kernel can be easily combined with these kernels
using a weighted average.
The kernel for drug compounds and the kernel for target
proteins can be combined using the Kronecker product Kd6Kt,
such that for drug-target pairs (di,ti) and (dj ,tj)
K((di,ti),(dj ,tj))~Kd(di,dj)Kt(ti,tj):
For each drug compound with at least one known interaction in
the training data, a score interaction profile y^ is computed from its
interaction profile y and the kernel matrix K , using the
Regularized Least Squared (RLS) classifier. This is achieved by
means of the simple closed form solution formula
y^~K(KzsI){1y,
where s is a regularization parameter.
We refer the reader to [16] for a more detailed description and
analysis of this method.
For simplicity in the sequel we call GIP the RLS algorithm that
uses the kernel defined as the Kronecker product of the weighted
averages of the interaction kernels and chemical and genomic
kernels.
Weighted Nearest Neighbor for New Drug Compounds
We want to extend GIP to new drug compounds, that is,
compounds for which no interaction is known. To this aim, we
propose a simple weighted nearest neighbor procedure. For a new
drug compound, its chemical similarity with other known drug
compounds and their corresponding profiles are used in order to
infer a score interaction profile for that drug compound.
Specifically, the score interaction profile ydWNN of a new drug
compound d is the weighted sum of the profiles of the drug
compounds in the training data, where a higher weight is assigned
to profiles of those drug compounds more similar to d. Let
y1, . . . ,ynd be the interaction profiles of the other compounds in
the dataset (that is, the rows of Y ), listed in decreasing order with
respect to their chemical similarity to d. Then
ydWNN~
Xnd
i~1
wiyi,
where the weights wi’s are computed using a given decay value
Tƒ1 as wi~Ti{1. For computational reasons we only sum over
drug compounds with weight at least 10{4. In our experiments we
choose the decay rate T with 5 fold cross-validation to maximize
AUC. We call the resulting procedure WNN.
An extension of GIP to handle new drug compounds using
WNN, hereafter called WNN-GIP, can be directly formulated: for
each new drug compound d, add ydWNN as new row to the matrix
Y and apply GIP to predict the score interaction profile y^ of d .
A Method to Show the Bias of a LOOCV Procedure
In a recent paper [17] the BLM-NII algorithm is introduced
and assessed using the following leave-one-out cross validation
(LOOCV) procedure. Each compound with only one interaction
in Y is treated as a ’new candidate’ in the cross validation and the
BLM-NII procedure is applied to it. We observe that in this way a
Predicting Interactions for New Drugs
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strong prior is implicitly used in the cross validation, namely the
fact that the considered compound had at least one interaction.
To illustrate how this prior introduces a bias on the results, we
consider the following simple procedure, called Const. Const
constructs an all ’1’s profile for the drug compounds or target
proteins with only one interaction.
We can incorporate Const into GIP in the same way as WNN,
giving the Const-GIP method. With this method all possible
interactions for drug/targets with only one interaction will be
ranked before interactions with drugs/targets that also have other
interactions. Essentially, for such interactions the method only has
to do half the work, since the fact that the drug/target is correct
can be known with certainty. In real world situations there are also
drug compounds that interact with none of the target under
consideration, and vice versa, which would invalidate the Const-
GIP method.
Experiments
We perform a comparative experimental analysis of the
proposed algorithms and two recently published methods [15,17].
Datasets
To this end we use the four drug-target interaction networks in
humans involving enzymes, ion channels, G-protein-coupled
receptors (GPCRs) and nuclear receptors from [12]. Table 1 lists
some properties of the datasets.
Drug-target interaction information was retrieved from the
KEGG BRITE [6], BRENDA [10], SuperTarget [9] and
DrugBank [7] databases. Chemical structures of the compounds
was derived from the DRUG and COMPOUND sections in the
KEGG LIGAND database [6]. The chemical structure similarity
between compounds was computed using SIMCOMP [21], which
tries to find a graph matching between two compound structures.
This resulted in a similarity matrix for the denoted by Sc, which
represents the chemical space. Amino acid sequences of the target
(human) proteins were obtained from the KEGG GENES
database [6]. Sequence similarity between proteins was computed
using a normalized version of Smith-Waterman score [22],
resulting in a similarity matrix denoted Sg, which represents the
genomic space.
These datasets are publicly available at http://web.kuicr.kyoto-
u.ac.jp/supp/yoshi/drugtarget/and http://cbio.ensmp.fr/ ˜ yya-
manishi/bipartitelocal/. They are used as current standard
benchmark data for comparing the performance of machine
learning algorithms for drug-target interaction. We use these
datasets as they are without adding new interactions from source
databases.
Results
We follow the experimental procedure adopted in [15,19].
Specifically, for each dataset, drug compounds are split into five
subsets of roughly equal size. Each subset is then used in turn as
the test set and training is performed on the data consisting of the
remaining four subsets. This procedure is repeated five times.
Results are assessed using the AUC and AUPR quality
measures, generally used in this type of studies. Specifically, the
ROC curve of true positives as a function of false positives is
computed, and the area under the ROC curve (AUC) is
considered as quality measure (see for instance [23]). Furthermore,
the precision-recall curve is computed, that is, the plot of the ratio
of true positives among all positive predictions for each given recall
rate. The area under this curve (AUPR) provides a quantitative
assessment of how well, on average, predicted scores of true
interactions are separated from predicted scores of true non-
interactions. Since there are few true drug-target interactions, the
AUPR is a more informative quality measure than the AUC, as it
punishes much more the existence of false positive examples found
among the top ranked prediction scores [20].
Average AUC and AUPR results and standard deviations are
reported in Table 2. They indicate that a WNN-GIP has slightly
better (average) AUC on all datasets except Enzyme. However,
WNN has slightly better AUPR than WNN-GIP. By itself the GIP
method does not work well in this setting, which is to be expected,
since it was not designed to handle new drugs.
To estimate the statistical significance of the AUC results we
used the method described in [24]. To determine significance of
the AUPR results we used bootstrapping.
Table 1. The number of drug compounds and target
proteins, their ratio, and the number of interactions in the
drug-target datasets from [12].
Dataset Drugs Targets nd/nt Interactions
Enzyme 445 664 0.67 2926
Ion Channel 210 204 1.03 1476
GPCR 223 95 2.35 635
Nuclear
Receptor
54 26 2.08 90
doi:10.1371/journal.pone.0066952.t001
Table 2. Results of 5 fold cross validation: average AUC and
AUPR over 5 runs.
Method AUC (std) AUPR (std) T (std)
Enzyme
GIP 0.685 (0.006) 0.150 (0.008)
WNN 0.819 (0.004) 0.299 (0.023) 0.809 (0.068)
WNN-GIP 0.861 (0.004) 0.280 (0.014) 0.908 (0.019)
KBMF2K 0.812 (0.004) 0.287 (0.021)
Ion Channel
GIP 0.637 (0.008) 0.179 (0.013)
WNN 0.757 (0.006) 0.249 (0.046) 0.535 (0.200)
WNN-GIP 0.775 (0.006) 0.233 (0.024) 0.730 (0.171)
KBMF2K 0.802 (0.006) 0.245 (0.023)
GPCR
GIP 0.679 (0.014) 0.260 (0.023)
WNN 0.848 (0.008) 0.308 (0.032) 0.713 (0.084)
WNN-GIP 0.872 (0.008) 0.311 (0.021) 0.702 (0.081)
KBMF2K 0.840 (0.009) 0.347 (0.028)
Nuclear Receptor
GIP 0.758 (0.026) 0.357 (0.060)
WNN 0.788 (0.027) 0.434 (0.068) 0.305 (0.205)
WNN-GIP 0.839 (0.023) 0.456 (0.065) 0.527 (0.103)
KBMF2K 0.810 (0.025) 0.354 (0.063)
Standard deviation is reported between parentheses. The best AUC and AUPR
results are indicated in bold, results that are not significantly different from the
best (at a~0:05) are indicated in italic.
doi:10.1371/journal.pone.0066952.t002
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The last column of table 2 lists the average value of the decay
rate T over the folds and repetitions. In general, the larger dataset
have a higher (slower) decay rate, which means that more
neighbors are taken into account.
Comparison with other Methods
We consider the two following recent methods: KBMF2K [15]
and BLM-NII [17].
KBMF2K is based on a Bayesian formulation that combines
dimensionality reduction, matrix factorization and binary classi-
fication for predicting drug-target interaction networks using only
chemical similarity between drug compounds and genomic
similarity between target proteins.
In BLM-NII a drug-target interaction for a new drug
compound d is inferred by constructing an estimated interaction
profile for d as follows. For each target, an entry of the profile for d
is defined as the sum of the similarity values of d and each of the
drug compounds interacting with that target. The resulting profile
is then used as label information to learn an interaction model for
d by means of the BLM method.
Comparison with KBMF2K. To compare results of WNN
and WNN-GIP with those reported in [15], we follow the
experimental procedure therein used (described in the previous
section). Table 2 also includes the AUC and AUPR for the
KBMF2K method. They indicate similar performance of
KBMF2K and the simpler WNN algorithm, and slightly better
overall results achieved by WNN-GIP, except on the Ion Channel
dataset.
We could test the prediction capability of the proposed methods
on unknown drug-target interactions of the given network using
the procedure adopted in [15]. Therein, the complete interaction
network for each dataset is used as training data, and the
predictions on non-interacting pairs in the training set are ranked
with respect to their interaction scores. However, since each drug
compound or target in the training set has at least one interaction,
we do not need to use WNN and the results are those of GIP. We
report the top five predicted interactions for each dataset in
Table 3. Highest ranked predicted new interactions for each of the datasets.
Rank Drug compound Target protein
Enzyme
M 1 D00574 Aminoglutethimide hsa1589 cytochrome P450, family 21, subfamily A,
polypeptide 2
C,M,D 2 D00542 Halothane hsa1571 cytochrome P450, family 2, subfamily E,
polypeptide 1
M,D 3 D00139 Methoxsalen hsa1543 cytochrome P450, family 1, subfamily A,
polypeptide 1
M 4 D00437 Nifedipine hsa1585 cytochrome P450, family 11, subfamily B,
polypeptide 2
C,M,D 5 D00437 Nifedipine hsa1559 cytochrome P450, family 2, subfamily C,
polypeptide 9
Ion Channel
D,K 1 D00438 Nimodipine hsa779 calcium channel, voltage-dependent, L
type, alpha 1S subunit
2 D00726 Metoclopramide hsa1138 cholinergic receptor, nicotinic, alpha 5
(neuronal)
C,D 3 D03365 Nicotine hsa1137 cholinergic receptor, nicotinic, alpha 4
(neuronal)
4 D02098 Proparacaine hydrochloride hsa8645 KCNK5: potassium channel, subfamily K,
member 5
K 5 D00552 Benzocaine hsa6331 sodium channel, voltage-gated, type V,
alpha subunit
GPCR
C,M,D 1 D00283 Clozapine hsa1814 dopamine receptor D3
C,D 2 D02358 Metoprolol hsa154 adrenoceptor beta 2, surface
3 D00604 Clonidine hydrochloride hsa147 adrenoceptor alpha 1B
C 4 D03966 Eglumetad hsa2914 glutamate receptor, metabotropic 4
C 5 D00255 Carvedilol hsa152 adrenoceptor alpha 2C
Nuclear Receptor
1 D00316 Etretinate hsa6096 RAR-related orphan receptor B
C 2 D00182 Norethindrone hsa2099 estrogen receptor 1
K 3 D00348 Isotretinoin hsa5915 retinoic acid receptor, beta
4 D01132 Tazarotene hsa6097 RAR-related orphan receptor C
K 5 D00348 Isotretinoin hsa5916 retinoic acid receptor, gamma
Interactions found in ChEMBL, Matador, DrugBank and KEGG are indicated in italic and marked as C, M, D and K respectively.
doi:10.1371/journal.pone.0066952.t003
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Table 3. The full lists of all predicted interactions ranked by
interaction score can be found in http://cs.ru.nl/˜tvanlaarhoven/
drugtarget2013/.
Comparison with BLM-NII. Table 4 shows the results of
the LOOCV experiments. As expected, both Const-GIP and
BLM-NII achieve very good results, with comparable AUC, and
slightly better AUPR performance achieved by Const-GIP. To
asses the statistical significance of these differences we used an
upper bound on the variance of the AUC and AUPR for BLM-
NII, because the actual variance is unknown. With this bound the
differences in AUC scores are not statistically significant.
In general, these results indicate that cross validation should be
applied and interpreted with care. Note that the cross validation
procedure used in the comparison with KBMF2K is also positively
biased, since we know that each ’new’ drug compound has at least
one interaction, but there the bias is much smaller.
Discussion
In this work, we proposed a simple yet effective procedure to
predict interaction profiles for unknown drug compounds and
show how it can be directly integrated into a recent machine
learning algorithm for the in-silico prediction of drug-target
interactions. The novelty of our approach comes in the use of a
weighted nearest neighbor procedure for inferring a profile for a
drug compound by using interaction profiles of the compounds in
the training data, where each profile is weighted using information
about chemical similarity between drug compounds integrated
with a simple decay scheme. The method can be directly modified
to predict interaction scores of unknown targets (or of both
unknown targets and drug compounds).
We performed a comparative assessment of the proposed
methods on four different drug-target interaction networks from
humans involving enzymes, ion channels, GPCRs and nuclear
receptors. Results indicated that WNN is competitive in predicting
interaction for unknown drug compounds with more involved
machine learning methods recently proposed, notably a fully
probabilistic method based on a Bayesian formulation that
combines kernel-based nonlinear dimensionality reduction, matrix
factorization and binary classification. Furthermore we showed
that the direct integration of WNN in a recent kernel based
machine learning method provides a general and powerful tool for
finding drug-target interactions.
The computational complexity of WNN is O(nd
2znt
2), while
the computational complexity of WNN-GIP is dominated by the
RLS prediction using the Kronecker product kernel, which is
O(nd
3znt
3) as implemented in [16], but can be further improved
yielding a quadratic computational complexity by applying recent
techniques for large-scale kernel methods for computing the two
kernel decompositions, e.g. [25]. Therefore WNN-GIP is more
efficient than KBMF2K, since the total time complexity of each
iteration in the variational approximation method used in
KBMF2K is O(Rnd
3zRnt
3zR3), where R is the subspace
dimensionality used in the method.
A limitation of our approach is that it does not make a
difference between an inactive target and a target that has not
been measured for a compound.
Compounds with a higher mutual chemical similarity also have
a higher chance of having the same bioactivity. This information
could be considered by WNN by determining directly the weights
from the similarity, instead of using the proposed ranking-based
decay mechanism. In this way all the compounds with high
similarity would be considered with a high weight and all the
compounds with low similarity would only have a minor
contribution to the final predicted profile. On the same reasoning
there is also a similarity threshold from where the chance is so low
that two compounds have the same profile that it would be better
not to predict something in the first place. In particular for new
screening data from very large screening libraries chances are high
that none of the references are really similar to the screening hits,
which would most likely have a detrimental effect in the overall
prediction performance, if predictions would be made for all such
compounds. Many published target prediction algorithms apply
such "applicability domain" or confidence estimations for their
predictions. WNN could be modified to address this issue for
instance by including a binary annotation based on a similarity
threshold, or a more advanced procedure based on the similarities
of all compounds considered for the generation of the profile.
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